Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Icecure Medical ( (ICCM) ) just unveiled an announcement.
On March 2, 2026, IceCure Medical announced that an independent, investigator-initiated study of its ProSense cryoablation system for treating benign breast tumors, or fibroadenomas, was published in the peer-reviewed journal PLOS One. Conducted at the Premier Med Healthcare, Training, and Research Institute in Hungary, the retrospective analysis of prospectively collected data found ProSense achieved a median fibroadenoma volume reduction of 80.6% at about six months and 92.9% at one year post-treatment.
The study, which evaluated larger lesions and the use of sequential cryoprobe relocations, concluded that ProSense cryoablation with a liquid nitrogen system was safe and effective, with multiple probe relocations preserving safety and efficacy. IceCure, whose ProSense device already has FDA clearance for fibroadenomas, views these results as reinforcing clinical adoption of minimally invasive cryoablation as an alternative to surgical excision and potentially influential for future treatment guidelines for non-cancerous breast tumors in key markets.
IceCure notes that fibroadenomas are the most common benign breast lesion, with surgical excision often used for large or symptomatic tumors, and estimates that cryoablation could be relevant for tens of thousands of U.S. cases annually. The company frames the new data as supporting the value proposition of ProSense in terms of minimal scarring, shorter procedures, and office-based treatment options for patients and providers.
The most recent analyst rating on (ICCM) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Icecure Medical stock, see the ICCM Stock Forecast page.
Spark’s Take on ICCM Stock
According to Spark, TipRanks’ AI Analyst, ICCM is a Neutral.
Icecure Medical’s overall stock score is primarily impacted by its challenging financial performance, with persistent losses and negative cash flows. The technical analysis indicates a bearish trend, and valuation metrics are weak due to unprofitability. However, the positive sentiment from the earnings call, driven by FDA approval and strategic market opportunities, provides some optimism for future growth.
To see Spark’s full report on ICCM stock, click here.
More about Icecure Medical
IceCure Medical Ltd. is an Israel-based medical device company that develops and markets liquid nitrogen-based cryoablation systems for minimally invasive destruction of benign and cancerous tumors. Its flagship ProSense system is cleared and approved in multiple markets, including the U.S., Europe, and Asia, with key focus areas in breast, kidney, bone, and lung cancer.
ProSense is designed to offer an alternative to surgical tumor removal through short, office-based procedures that aim to reduce pain, complications, and recovery time. By leveraging large lethal freezing zones, the system targets both small and larger lesions, positioning IceCure within the growing segment of image-guided, minimally invasive oncology treatments.
Average Trading Volume: 287,907
Technical Sentiment Signal: Sell
Current Market Cap: $39.69M
See more data about ICCM stock on TipRanks’ Stock Analysis page.